DuPont’s nutrition and bioscience business may be up for sale and Amsterdam’s Royal DSM may want to buy it, according to a report from Bloomberg.
Download Now: To be a profitable investor you first need to know the rules. Get Jim Cramer’s 25 Rules for Investing Special Report
The business could be valued at $25 billion, people who asked not to be identified told Bloomberg.
The specialty chemicals maker has been considering the sale or spinoff of its nutrition business, and has been in the process of selecting advisers to sort out offers for the division for some time, according to confidential sources.
In August, Bloomberg said that DuPont wanted to rid itself of the arm, and may be looking into a Reverse Morris Trust, a tax-free merger, as well.
Shares of DuPont fell 1.41% to $72.50 on Monday.
By Cherella Cox Owoyelu
Source: The Street
LinkedIn Twitter Xing Facebook EmailJohnson Matthey plc (JM; London, U.K.) is expanding its fuel cell operations into China with a £7.5-million facility to manufacture critical components for customers in the […]
LinkedIn Twitter Xing Facebook EmailBorealis Group AG (Vienna, Austria) announced that its new naphtha cavern in Porvoo, Finland has now been safely commissioned as of October 2020. Having invested around […]
LinkedIn Twitter Xing Facebook EmailMitsubishi Chemical Holdings, Japan’s largest chemical maker, has named Jean-Marc Gilson, CEO of plant-ingredients maker Roquette Frères (Lestrem, France), as its next CEO, effective 1 April […]
